Alumis Inc. Common Stock ALMS · Stock Open Alumis Inc. Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
Alumis Inc. Common Stock Analysis (ALMS)
Is Alumis Inc. Common Stock a good investment? Alumis Inc. Common Stock (ALMS) is currently trading at 6.55 USD. Market analysts have a consensus price target of 31.13 USD. This suggests a potential upside from current levels.
Earnings Schedule: Alumis Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -2.87.
Investor FAQ
Does Alumis Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Alumis Inc. Common Stock?
Alumis Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -3.86.
Company Profile
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Community Discussion